blissel vag.gel 50mcg/g
itf hellas ΜΟΝΟΠΡΟΣΩΠΗ ΑΝΩΝΥΜΗ ΕΜΠΟΡΙΚΗ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΗ ΕΤΑΙΡΕΙΑ Δ.Τ. itf hellas s.a. Αρεως 103 & Αγίας Τριάδος 36,, 175 62 17562, Π. Φάληρο 210.9373332 - estriol - vag.gel (ΚΟΛΠΙΚΗ ΓΕΛΗ) - 50mcg/g - estriol 50mcg - estriol
blissel 50mcg/g vaginal gel
itf hellas a.e. (0000008180) areos 103 and agias triados 36, palaio faliro, 17562 - estriol - vaginal gel - 50mcg/g - estriol (0000050271) 50ug
elfabrio
chiesi farmaceutici s.p.a - pegunigalsidase alfa - fabry disease - Άλλα προϊόντα πεπτικής οδού και μεταβολισμού, - elfabrio is indicated for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of fabry disease (deficiency of alpha-galactosidase).
libeprosta c.tab 80mg/tab
pierre fabre farmaka ae Μεσογείων 350,, 153 41 153 41, Αγ. Παρασκευή 210.7234582 - serenoa repens lipidosterolic extract - c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΔΙΣΚΙΟ) - 80mg/tab - serenoa repens lipidosterolic extract 80mg - serenoa repens
airol 0,05% (w/w) κρεμα
pierre fabre hellas ae (0000003304) Λεωφ. Μεσογείων 350 & Θράκης 64,, 153 41, Αγία Παρασκευή, 153 41 - tretinoin - ΚΡΕΜΑ - 0,05% (w/w) - 0000302794 tretinoin 0.500000 mg - tretinoin
clopidogrel taw pharma (previously clopidogrel mylan)
taw pharma (ireland) limited - υδροχλωρική κλοπιδογρέλη - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - Αντιθρομβωτικοί παράγοντες - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:, - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). , - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.
lenalidomide/pharmazac caps 2.5mg/cap
ΦΑΡΜΑΖΑΚ ΑΝΩΝΥΜΗ ΦΑΡΜΑΚΕΥΤΙΚΗ ΕΜΠΟΡΙΚΗ ΒΙΟΜΗΧΑΝΙΚΗ ΕΤΑΙΡΕΙΑ Δ.Τ. pharmazac ae Ναούσης 31, Βοτανικός,, 104 47 104 47, Αθήνα 210.3418889-97 - lenalidomide - caps (ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ) - 2.5mg/cap - lenalidomide 2,5mg - lenalidomide
lenalidomide/pharmazac caps 5mg/cap
ΦΑΡΜΑΖΑΚ ΑΝΩΝΥΜΗ ΦΑΡΜΑΚΕΥΤΙΚΗ ΕΜΠΟΡΙΚΗ ΒΙΟΜΗΧΑΝΙΚΗ ΕΤΑΙΡΕΙΑ Δ.Τ. pharmazac ae Ναούσης 31, Βοτανικός,, 104 47 104 47, Αθήνα 210.3418889-97 - lenalidomide - caps (ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ) - 5mg/cap - lenalidomide 5mg - lenalidomide
lenalidomide/pharmazac caps 20mg/cap
ΦΑΡΜΑΖΑΚ ΑΝΩΝΥΜΗ ΦΑΡΜΑΚΕΥΤΙΚΗ ΕΜΠΟΡΙΚΗ ΒΙΟΜΗΧΑΝΙΚΗ ΕΤΑΙΡΕΙΑ Δ.Τ. pharmazac ae Ναούσης 31, Βοτανικός,, 104 47 104 47, Αθήνα 210.3418889-97 - lenalidomide - caps (ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ) - 20mg/cap - lenalidomide 20mg - lenalidomide